Daxor's blood volume analysis uncovers hidden heart failure subtype in nearly 1 in 5 patients, enabling targeted treatment

Case reports in the journal of the american college of cardiology underscore the critical role of blood volume analysis in optimizing heart failure treatment oak ridge, tn, feb. 14, 2025 (globe newswire) -- daxor corporation (nasdaq: dxr), the global leader in blood volume measurement technology, today announces a groundbreaking case series published in jacc: case reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated red blood cells, opening new avenues for targeted treatment through therapeutic phlebotomy. in the study, researchers evaluated 179 advanced heart failure patients using daxor's blood volume analysis (bva).
DXR Ratings Summary
DXR Quant Ranking